MTSR - NASDAQ

Metsera, Inc.

MTSR·NASDAQ

$70.50

+0.0000%

HealthcareBiotechnology

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$7.43B

EPS-2.0300

P/E Ratio-34.73

Earnings Date03/25/2026

No Revenue Data

MTSR has not reported any revenue values in the available annual periods.

-209.13M

Net Income

343%

3Y+343.0%

5Y+343.0%

10Y+343.0%

-99.79M

Operating Cash Flow

182%

3Y+182.0%

5Y+182.0%

10Y+182.0%

Metsera, Inc. Profit Bridge

MTSR · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (224.83M)

Operating Income-224.83M

Other Income & Taxes

Interest Expense (223.00K)

Other Income/Expense6.37M

Pretax Income-218.47M

Income Tax (-9.34M)

Net Income-209.13M

Net Income

-209.13M

Profitability Analysis

Metsera, Inc. Income Statement

MTSR • NASDAQ

Metsera, Inc. Income Statement	Dec 2024	Dec 2023
REVENUE
GROSS PROFIT
OPERATING INCOME
Operating Expenses	(224.8M)	(43.7M)
Selling, General & Administrative	(26.8M)	(15M)
Research & Development	(107.5M)	(15.6M)
Operating Income	-224.8M	-43.7M
PRE-TAX INCOME
Interest Expense	(223K)	(0.0)
Net Interest Income	6M	1.9M
Other Expenses	(90.5M)	(13.1M)
Total Other Income Expenses Net	6.4M	-3.5M
Income Before Tax	-218.5M	-47.2M
NET INCOME
Income Tax Expense	-9.3M	(0.0)
Net Income	-209.1M	-47.2M

SEC Filings

MTSR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	November 13, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 07, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	October 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 29, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 29, 2025	September 29, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 22, 2025	September 21, 2025	2025	View Filing

Showing 1 to 10 of 22 filings

Related Guides

Blog Categories

Continue your MTSR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.